Oligonucleotide CMCkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Oligonucleotide CMC
keyboard_arrow_leftSearch & Filter
search
Free / Premium
Streams
Formats
Topics
Oligonucleotide CMC
search
Free / Premium
Streams
Formats
Topics
On Demand - For MembersFree
On-Demand Presentations
Characterization of the Diastereoisomeric Composition of Phosphorothioate Oligonucleotides
- Claus Rentel, PhD - Executive Director, Analytical Development/QC, Ionis Pharmaceuticals, Inc.
On Demand - For MembersFree
Whitepapers & Case Studies
WHITEPAPER: From Research to Commercial Quantities: A Seamless Supply of Oligonucleotides
On Demand Free
Interviews
Boosting Commercialization of Oligonucleotides as a Raw Materials Supplier with Aldevron
On Demand - For MembersFree
Scientific Posters
Large Scale Manufacturing for Oligonucleotide API
On Demand - For MembersFree
Whitepapers & Case Studies
CASE STUDY: Scaling Up Manufacturing When it’s Needed Most
On Demand - For MembersFree
Interviews
Oligonucleotides @ Bachem - Interview with Torsten Wöhr
- Torsten Wöhr, Ph.D. - Head of Oligonucleotides, Bachem AG
On Demand - Premium Only
On-Demand Presentations
The Evolution of Regulation for Oligonucleotide Therapeutics: Regulatory Agency Perspectives
- René Thürmer, PhD - Deputy Head, Unit Pharmaceutical Biotechnology, BfArM Federal Institute for Drugs and Medical Devices
On Demand - For MembersFree
Whitepapers & Case Studies
WHITEPAPER: Oligonucleotide Purification and Analysis: A Chromatography Overview
On Demand - Premium Only
On-Demand Presentations
Regulatory Considerations for Setting Smart Starting Material Specifications
- Dominik Altevogt, Ph.D - Pharma Technical Regulatory Manager, F.Hoffmann-La Roche Ltd
On Demand - For MembersFree
Whitepapers & Case Studies
WHITEPAPER: Oligonucleotide API Manufacturing and CMC Services
On Demand - Premium Only
On-Demand Presentations
Learnings from Process Validation of an Oligonucleotide and Plans for Leveraging the Platform in the Future
- Jesse Faber - Senior Engineer III, ASO Process Engineering and M, Biogen
On Demand - Premium Only
On-Demand Presentations
Introduction into Identity Testing Strategies and Development of a Sequence Sensitive Method Using In-source Fragmentation on A Low-resolution LC-MS Instrument
- Tom Atherton, Ph.D. - Senior Scientist, GlaxoSmithKline
On Demand - Premium Only
On-Demand Presentations
Doing an IND with An NDA in Mind: Planning for Regulatory Interactions
- Jennifer Franklin - Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
On Demand - Premium Only
On-Demand Presentations
Switching Gears, From Early Stage Development to Late Stage Validation in 4 Years
- Hans Kistemaker, PhD - Senior Scientist, Chemistry & Manufacturing, ProQR Therapeutics
On Demand - Premium Only
On-Demand Presentations
Accelerated Stability Assessment of Oligonucleotides
- Mark Madsen, PhD - Assistant Director, Analytical Development & Quality Control, Ionis Pharmaceuticals
On Demand - Premium Only
On-Demand Presentations
From Amidites to Drug Product: Quality Control Analysis of Oligonucleotide Therapeutics
- Carolyn Mazzitelli - Associate Director, Ionis Pharmaceuticals
On Demand - Premium Only
On-Demand Presentations
Phase Appropriate Analytical Control Strategies for Oligonucleotides
- Jessica Stolee, PhD - Associate Director, Pharma and ASO Analytical Deve, Biogen
On Demand - Premium Only
On-Demand Presentations
Overview of Current Technical Challenges in Oligonucleotide CMC
- Marc Lemaître, PhD - Chief Operating Officer / Principal, Sirnaomics, Inc. / ML Consult
On Demand - Premium Only
On-Demand Presentations
Liquid Phase Synthesis of Oligonucleotides
- Andrew Livingston - Professor of Chemical Engineering, Imperial College London
On Demand - Premium Only
On-Demand Presentations
Advances in the Chromatographic Purification of Oligonucleotides
- Andrew Rodriguez, PhD - Assistant Director, Process Chemistry, Ionis Pharmaceuticals
On Demand - Premium Only
On-Demand Presentations
Control of Impurities and Overall Purity in GalNAc siRNA Conjugates
- John Richards, Ph.D. - Global Drug Development/Technical Research & Development, Novartis
On Demand - Premium Only
On-Demand Presentations
QBD and DoE Approaches to Oligos – Applications for Process Robustness
- Thomas Emery - Associate Scientist, GSK
On Demand - Premium Only
On-Demand Presentations
Early Phase CMC and Regulatory Strategy for Oligonucleotides
- Marc Lemaître, PhD - Chief Operating Officer / Principal, Sirnaomics, Inc. / ML Consult
On Demand - Premium Only
On-Demand Presentations
A Platform Stability Strategy for Anti-Sense Oligonucleotides: Part I - ASO Degradation Study and Predicative Stability Modelling
- Jiangwei Li, PhD - Scientist, Analytical Development, Biogen
On Demand - Premium Only
On-Demand Presentations
A Platform Stability Strategy for Anti-Sense Oligonucleotides: Part II - ASO program ICH Stability and Future Platform Strategy
- Philip Pue-Gilchrist - Scientist, Analytical Development, Biogen
On Demand - Premium Only
On-Demand Presentations
“Points-to-Consider” When Planning Your First Oligonucleotide Drug Product Campaign
- Stefan Vonhoff, Ph.D. - Vice President CMC, NOXXON Pharma AG
On Demand - Premium Only
On-Demand Presentations
Terminal Sterilisation of Oligonucleotide Drug Products
- Angela Wagner, PhD - Associate Principal Scientist, Sterile & Specialty, Merck Sharpe & Dohme
Filter
Free / Premium
Streams
Formats
Topics